Background and Objective: Burkitt’s lymphoma (BL) is a specific type of non-Hodgkin lymphoma. The BL is characterized by rapid progression and a tendency to metastasize the bone marrow and central nervous system. This study aims to evaluate the anticancer potential of choline and CDP-choline on BL cells (Ramos cells), in vitro. Materials and Methods: Ramos cells were treated with increasing concentrations of doxorubicin, choline and CDP-choline for 24 hrs after which cell viability was assessed using the MTT assay. Cytokine levels (IL-6 and TNF-α) and reactive oxygen species (ROS) production were measured using ELISA and fluorometric kits, respectively. One-way Analysis of Variance (ANOVA) with post hoc Tukey-Kramer multiple comparison tests were used for the statistical analysis, p<0.05 was accepted as a statistically significant level. Results: Choline and CDP-choline treatment for 24 hrs decreased Ramos cell viability, with IC50 values of 100, 02 and 5.45 μM, respectively. Both treatments increased ROS levels, indicating induction of oxidative stress. However, treatment of Ramos cells with these agents for 24 hrs did not induce cytokines (IL-6 and TNF-α) production. Choline treatment increased supernatant choline levels, whereas CDP-choline had no significant effect on intracellular choline in Ramos cells. Conclusion: Choline and CDP-choline reduced cell viability of Ramos cells probably via ROS dependent mechanism, but did not induce inflammatory responses at 24 hrs post-treatment. These findings suggested the possible anticancer potential of choline and CDP-choline against BL. This warrants further investigation into their potential therapeutic implications.